RT Journal Article
SR Electronic
T1 Two decades of molecular surveillance in Senegal reveal changes in known drug resistance mutations associated with historical drug use and seasonal malaria chemoprevention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.24.23288820
DO 10.1101/2023.04.24.23288820
A1 Ndiaye, Yaye Die
A1 Wong, Wesley
A1 Thwing, Julie
A1 Schaffner, Stephen S
A1 Tine, Abdoulaye
A1 Diallo, Mamadou Alpha
A1 Deme, Awa
A1 Sy, Mouhammad
A1 Bei, Amy K
A1 Thiaw, Alphonse B
A1 Daniels, Rachel
A1 Ndiaye, Tolla
A1 Gaye, Amy
A1 Ndiaye, Ibrahima Mbaye
A1 Toure, Mariama
A1 Gadiaga, Nogaye
A1 Sene, Aita
A1 Sow, Djiby
A1 Garba, Mamane N.
A1 Yade, Mamadou Samba
A1 Dieye, Baba
A1 Diongue, Khadim
A1 Zoumarou, Daba
A1 Ndiaye, Aliou
A1 Gomis, Jules
A1 Fall, Fatou Ba
A1 Ndiop, Medoune
A1 Diallo, Ibrahima
A1 Sene, Doudou
A1 Macinnis, Bronwyn
A1 Seck, Mame Cheikh
A1 Ndiaye, Mouhamadou
A1 Badiane, Aida S.
A1 Hartl, Daniel L.
A1 Volkman, Sarah K.
A1 Wirth, Dyann F.
A1 Ndiaye, Daouda
YR 2023
UL http://medrxiv.org/content/early/2023/04/26/2023.04.24.23288820.abstract
AB Drug resistance in Plasmodium falciparum is a major threat to malaria control efforts. We analyzed data from two decades (2000-2020) of continuous molecular surveillance of P. falciparum parasite strains in Senegal to determine how historical changes in drug administration policy may have affected parasite evolution. We profiled several known drug resistance markers and their surrounding haplotypes using a combination of single nucleotide polymorphism (SNP) molecular surveillance and whole-genome sequence (WGS) based population genomics. We observed rapid changes in drug resistance markers associated with the withdrawal of chloroquine and introduction of sulfadoxine-pyrimethamine in 2003. We also observed a rapid increase in Pfcrt K76T and decline in Pfdhps A437G starting in 2014, which we hypothesize may reflect changes in resistance or fitness caused by seasonal malaria chemoprevention (SMC). Parasite populations evolve rapidly in response to drug use, and SMC preventive efficacy should be closely monitored.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPACTR 202003802011316Funding StatementThe work was supported by the NIH/ICEMR, International Centre of Excellence for Malaria Research, west Africa (U19AI089696) and the Bill and Melinda Gates Foundation (0PP1200177).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the Ministry of Health and Social Action in Senegal (Protocol SEN14/49) and the Institutional Review Board at Harvard TH Chan School of Public Health (CR-16330-07).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors